We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

175 hedge funds and large institutions have $819M invested in Verve Therapeutics in 2025 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 50 increasing their positions, 68 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

122% more capital invested

Capital invested by funds: $369M → $819M (+$450M)

8% less funds holding

Funds holding: 191 → 175 (-16)

9.11% less ownership

Funds ownership: 90.95% → 81.84% (-9.1%)

25% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 57

26% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 68

86% less call options, than puts

Call options by funds: $5.84M | Put options by funds: $41.9M

Holders
175
Holders Change
-16
Holders Change %
-8.38%
% of All Funds
2.3%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
43
Increased
50
Reduced
68
Closed
57
Calls
$5.84M
Puts
$41.9M
Net Calls
-$36M
Net Calls Change
-$36.8M

Top Buyers

Rank Fund Capital Flow
1
PCM
Pentwater Capital Management
Florida
+$38.3M
2
AAM
Alpine Associates Management
Florida
+$15.6M
3
FCM
Farallon Capital Management
California
+$15.4M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$9.96M
5
UBS Group
UBS Group
Switzerland
+$9.91M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$31.6M
2
SSA
Schonfeld Strategic Advisors
New York
-$15.7M
3
NHAS
Novo Holdings A/S
Denmark
-$13.7M
4
WP
Woodline Partners
California
-$12.6M
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$11.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$5.7M -$2.37M -416,545 -45%
Bank of America
27
Bank of America
North Carolina
$5.46M -$6.54M -1,147,073 -70%
ACM
28
ADAR1 Capital Management
Texas
$5.27M +$2.67M +469,018 New
Two Sigma Advisers
29
Two Sigma Advisers
New York
$4.28M +$1.18M +207,500 +119%
OAC
30
OMERS Administration Corp
Ontario, Canada
$4.17M +$2.12M +371,200 New
WIC
31
Water Island Capital
New York
$3.77M +$1.91M +335,593 New
NCM
32
Nantahala Capital Management
Connecticut
$3.72M +$1.89M +331,437 New
GCIA
33
Gabelli & Co Investment Advisers
New York
$3.4M +$1.72M +302,400 New
Barclays
34
Barclays
United Kingdom
$3.39M +$653K +114,631 +61%
Wellington Management Group
35
Wellington Management Group
Massachusetts
$3.35M +$311K +54,505 +22%
Citadel Advisors
36
Citadel Advisors
Florida
$3.23M -$134K -23,476 -8%
GF
37
Gabelli Funds
New York
$3M +$1.52M +267,520 New
TI
38
Trexquant Investment
Connecticut
$2.58M -$2.04M -358,636 -61%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$2.48M -$24.2K -4,246 -2%
AA
40
AQR Arbitrage
Connecticut
$2.34M +$1.19M +208,700 New
Jane Street
41
Jane Street
New York
$2.23M +$558K +97,923 +97%
UBS AM
42
UBS AM
Illinois
$2.06M +$285K +50,044 +37%
Citigroup
43
Citigroup
New York
$1.98M +$203K +35,686 +25%
SSA
44
Schonfeld Strategic Advisors
New York
$1.98M -$15.7M -2,747,137 -94%
AQR Capital Management
45
AQR Capital Management
Connecticut
$1.93M -$1.15M -201,387 -54%
American Century Companies
46
American Century Companies
Missouri
$1.9M +$104K +18,292 +12%
Invesco
47
Invesco
Georgia
$1.61M +$331K +58,085 +68%
Millennium Management
48
Millennium Management
New York
$1.55M -$11.2M -1,972,550 -93%
CCM
49
Chicago Capital Management
Illinois
$1.41M +$715K +125,377 New
FT
50
Fiduciary Trust
Massachusetts
$1.35M +$228K +40,000 +50%
1
2
3 4 5

VERV Hedge Fund Activity: Q2 2025 in Review

175 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2025, worth a combined $819M — up 122% from $369M a quarter earlier.

Sellers outnumbered buyers: 57 funds closed out of VERV and 43 opened new positions — a net loss of 14 holders — while 68 trimmed existing stakes and 50 added.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $38.3M. The largest seller was BVF Inc, exiting entirely with an estimated $31.6M sold.

  • 175 institutional investors held Verve Therapeutics (VERV) as of Q2 2025, down from 191 in Q1 2025.
  • Funds reported $819M of Verve Therapeutics stock for Q2 2025, up 122% quarter-over-quarter.
  • 43 funds opened new Verve Therapeutics positions in Q2 2025 and 57 closed out, a net change of -14 holders.
  • The largest Verve Therapeutics buyer in Q2 2025 was Pentwater Capital Management, an estimated $38.3M added.
  • The largest Verve Therapeutics seller in Q2 2025 was BVF Inc, an estimated $31.6M sold.

Based on aggregated 13F filings for Q2 2025.